Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors

A method of treating a patient with a therapeutic agent that treats or inhibits a respiratory disorder and an Arachidonate 15-Lipoxygenase (ALOX15) inhibitor, wherein the patient is suffering from a respiratory disorder, the method comprising:

• determining whether the patient has an ALOX15 predicted loss-of-function variant nucleic acid molecule encoding a human ALOX15 polypeptide by:
• obtaining or having obtained a biological sample from the patient;
• and
• performing or having performed a genotyping assay on the biological sample to determine if the patient has a genotype comprising the ALOX15 predicted loss-of-function variant nucleic acid molecule;
• and
• administering or continuing to administer to the patient the therapeutic agent that treats or inhibits a respiratory disorder in a standard dosage amount, and administering to the patient an ALOX15 inhibitor when the patient is ALOX15 reference;
• or
• administering or continuing to administer to the patient the therapeutic agent that treats or inhibits a respiratory disorder in an amount that is lower than a standard dosage amount, and administering to the patient an ALOX15 inhibitor when the patient is heterozygous for the ALOX15 predicted loss-of-function variant;
• wherein the presence of a genotype having the ALOX15 predicted loss-of-function variant nucleic acid molecule encoding the human ALOX15 polypeptide indicates the patient has a reduced risk of developing a respiratory disorder.

A method of identifying a human subject having an increased risk for developing a respiratory disorder, wherein the method comprises:

• determining or having determined the presence or absence of an ALOX15 predicted loss-of-function variant nucleic acid molecule encoding a human ALOX15 polypeptide in a biological sample obtained from the subject;
• wherein:
• when the human subject is ALOX15 reference, then the human subject has an increased risk for developing a respiratory disorder;
• and
• when the human subject is heterozygous for an ALOX15 predicted loss-of-function variant or homozygous for an ALOX15 predicted loss-of-function variant, then the human subject has a decreased risk for developing a respiratory disorder.